Rani Therapeutics Holdings RANI
NASDAQ RANI
$0.57 +0.01 (+1.41%)
At close: Nov 11, 2026 · 4:00 PM EST

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021)

Updated

Rani Therapeutics Holdings (RANI) reported Preferred Stock Liabilities of $191.03 million for Q2 2021, up 65.4% from $115.51 million a year earlier and unchanged from the prior quarter.

Analysis

Rani Therapeutics Holdings (RANI) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Rani Therapeutics Holdings posted Preferred Stock Liabilities of $184.71 million.

  • Per Business Quant data, the three quarters before Q2 2021 came in at $191.03 million (Q1 2021), $184.71 million (Q4 2020) and $115.51 million (Q3 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Rani Therapeutics Holdings 111.44 Mn -41.89 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 191.03 Mn
Mar 31, 2021 191.03 Mn
Dec 31, 2020 184.71 Mn
Sep 30, 2020 115.51 Mn
Jun 30, 2020 115.51 Mn
API Access

Rani Therapeutics Holdings Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RANI&period=max&api_key=YOUR_API_KEY